Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective.

Published in: Journal of medical economics (2024)

Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.

Keyphrases